Arterra Bioscience Spa · MIL:ARBS

Arterra Bioscience Spa — Integrae SIM Financial Galà 2025

23 slides from Arterra Bioscience Spa's conference presentation, Jun 19, 2025

  1. Slide 1: Integrae SIM Financial Galà, Milan LUISS Hub

    INTEGRÆ SIM Financial Galà Milan LUISS Hub June 19th, 2025

  2. Slide 2: Index

    Index TOPICS • ARTERRA AT GLANCE • MARKET CONSOLIDATION & DIVERSIFICATION • FINANCIALS

  3. Slide 3: People Speaking Today

    People Speaking Today MARIDA BIMONTE GUALTIERO IOIMO Grant & IP Director CFO and Investor Relations Manager

  4. Slide 4: Arterra Bioscience - Innovative SME

    Arterra Bioscience - Innovative SME Arterra Bioscience Is a biotech company listed on the “Euronext Growth Milan” market of Borsa Italiana since 2019, founded in Naples by M. Gabriella Colucci in 2004 with the aim of developing technologies and innovative solutions that find application in various i

  5. Slide 5: Arterra Organization

    ARTERRA ORGANIZATION INTEGRæ SIM Financial Galà Milan LUISS Hub June 19 th, 2025

  6. Slide 6: Arterra & Vitalab Team

    Arterra & Vitalab Team 31 10 PhD 12 Chem Ing 1 MSc 9 Tech 11 Administration 6 PhD Students 2 1256 Sqm

  7. Slide 7: Our facilities

    Our facilities Chemistry Lab Plant Cell Culture Lab Microbiology Lab Molecular & Cell Biol. Lab Histology & Microscopy Lab Production Lab Plant Cell Culture Growing Facility MicroAlgae Growing Facility Plant Growing Facility Lactobacillus Growing Facility

  8. Slide 8: Management team

    Management team MARIDA BIMONTE M. GABRIELLA COLUCCI VINCENZO FOGLIANO Grant & IP CEO Scientific Director Director GUALTIERO IOIMO GIUSEPPE FERRANTE ANNALISA TITO CFO & Investor COO Cell & Mol Biol. Director Relations Manager

  9. Slide 9: Company organization

    Company organization President & CEO Gabriella Colucci Chief Operating Officer CFO and Investor Relations Manager Giuseppe Ferrante Gualtiero Ioimo Cell Colture Extraction & PF Scientific Director Quality Control Vincenzo Fogliano Luigi Sena Logistic Cell & Molecular Biology Director Vitalab: Market

  10. Slide 10: Arterra position in relevant markets

    Arterra position in relevant markets Ingredients for: Ingredients for: Consumer cosmetics Beauty Cosmetics Skin Care, Make-Up, Personal Cair & Professional Cosmetic Products for topical Hair Care applications in Aestetic Medicine consolidated market through Intercos & New segment of a known market V

  11. Slide 11: Innovation in COSMETICS

    Innovation in COSMETICS CONSOLIDATED SEGMENT: SKIN CARE & MAKE-UP & HAIRCARE 2024/2025 Tito A, et All. Skin rejuvenating properties of a powerful blend of Gardenia jasminoides peptides and flavonoids.HPC Today, 1/2024. PCT/EP2024/074175. Use of plant-derived extracts for hair growth Di Lorenzo R, et

  12. Slide 12: Innovation in COSMETICS: New products on the market

    Innovation in COSMETICS 8 New products on the market Vita Gly-Jasmine Cordys Revitagen Vita D-Light Vita RisePeptides Jasminum Sambac Cordyceps sinensis Corthellus shiitake Hydrolyzed Rice Bran Plant cell extract extract extract Extract Vita PeptiBloom Vita NiaCeraMine PlantExo Vita Vita TechCollage

  13. Slide 13: Regulatory Achievements

    Regulatory Achievements China State Council released the final version of CSAR on 01 January 2021 and replaced the existing Cosmetics Hygiene Supervision Regulations China’s new cosmetics regulation include many changes: New cosmetic definitions, scope and classifications Management of new cosmetic

  14. Slide 14: Innovation in COSMETICS started in 2023

    Innovation in COSMETICS started in 2023 Powder active ingredients for make- CC market in up application 2025 Recombinant peptides using molecular CME CC market in market in farming technology* 2025 2025 Post-Biotics using precision CC fermentation Technology market CME CC Extracellular Vescicles EV

  15. Slide 15: Exosomes: The new wave Opportunity

    EXOSOMES: The new wave «Opportunity» Source: Graça Raposo, Willem Stoorvogel, JCB Feb 18,2013 Exosomes and EVs are extracellular vesicles released by all cells (eukaryotic or prokaryotic) having a number of complex biological funtions. o They are surrounded by a lipidic membrane protecting their car

  16. Slide 16: Plant Exosomes in professional beauty treatments today

    Plant Exosomes in professional beauty treatments today Source: Zhang B, Gong J, He L, Khan A, Xiong T, Shen H and Li Z (2022). Exosomes based advancements for application in medical aesthetics. Front. Bioeng. Biotechnol. 10:1083640. doi: 10.3389/fbioe.2022.1083640

  17. Slide 17: Our Exosome

    Our Exosome Insolated from sterile grown cell culture and in liquid sterile grown microgreens CME CC Clean & Bio market in market in • No Biological contamination 2025 2025 • No chemical contaminattion • Never exposed to environmental pollution • Standardized conditions: no variability due to coltiv

  18. Slide 18: The Beauty of Biotech: ONE for MANY

    The Beauty of Biotech: ONE for MANY Arterra + Vitalab In giving value to bio-knowledge Cell Culture Biomass 2 kg PF Hydrosoluble + 2 kg PF Liposoluble CC market in 200 gr Or 500 ml 1 kg PF CC CME market market Cell Culture MultiPeptides in in 2025 1 week Or PDRN CC CME (Polydeoxyribonucleotide) mark

  19. Slide 19: Financials

    FINANCIALS INTEGRæ SIM Financial Galà Milan LUISS Hub June 19th, 2025

  20. Slide 20: Economic results as of December 31, 2024

    32,15% Economic results as of December 31, 2024 Value of Production (€/000) Ebitda (€/000) Net Income (€/000) 2500 40,2% 26,7% 5.303 5.266 25,4% 4.951 35 2.133 1.414 498 32,5% 1.337 231 2000 21,7% 1.058 32,1% 1.712 1.076 1.242 1.416 1.591 1500 1000 4.173 3.564 3.304 500 2022 2023 2024 0 2022 2023 20

  21. Slide 21: Net Debt / Equity

    Net Debt / Equity Net Debt (€/000) Equity (€/000) 11.423 2022 2023 2024 Cash and Cash Equivalents (4.393) (3.686) (3.343) 10.751 10.467 Current Financial Receivables - - - 891 Financial assets other 1.823 than fixed assets (1.598) Current Financial Debt 174 86 96 Current Net Debt (5.817) (3.599) (3.

  22. Slide 22: Difference between 2024 and 2023

    Difference between 2024 and 2023 €4.500,00 €4.172,90 +28 €4.000,00 % The total turnover has increased by 28%. €3.519,14 €3.500,00 +34 % €3.254,75 The main difference between the 2024 and €3.000,00 the 2023 is the sale of raw materials, €2.632,67 €2.500,00 which has increased by 34%. €2.000,00 Additi

  23. Slide 23: Thank You!

    INTEGRÆ SIM Financial Galà Milan LUISS Hub THANK YOU!

Arterra Bioscience — Integrae SIM Financial Galà 2025 on 6ix